Business Wire

Veeva CRM Engage Webinar Makes Virtual Events Easy and Compliant for Life Sciences

Jaa

Today at Veeva European Commercial & Medical Summit, one of the largest life sciences events for commercial and medical affairs professionals in Europe, Veeva Systems (NYSE:VEEV) announced the availability of Veeva CRM Engage Webinar, the first purpose-built application to manage compliant virtual events in the life sciences industry. Veeva CRM Engage Webinar helps companies easily manage online events without compliance risk. Now marketing and medical affairs teams can open up an important digital channel to increase their reach to healthcare professionals (HCPs) and meet physicians’ growing expectations for online engagement.

Nearly all physicians (96%) say they would benefit from attending events online.1 Disparate event management systems, technology limitations, and regulatory challenges make it difficult for companies to conduct virtual events, despite the growing desire among HCPs to engage digitally with life sciences companies.

Veeva CRM Engage Webinar enables the life sciences industry to more effectively and efficiently connect with HCPs through virtual events. The application is built on Veeva CRM Events Management for a single, integrated solution to manage both physical and online events, from inviting attendees to post-event follow-up.

Also, integration with Veeva Vault ensures speakers only share approved compliant content, while Veeva CRM validates attendee credentials and gives an entire organization full visibility into interactions with HCPs across multiple channels. Now companies can deliver a seamless event experience and give HCPs faster, easier access to the content they need.

“Online events are one of the most effective and efficient ways for marketing and medical affairs teams to reach more HCPs through the channels and mobile devices they prefer,” said Andy Fuchs, senior director of commercial strategy at Veeva. “With Veeva CRM Engage Webinar, the life sciences industry finally has a purpose-built application for virtual events that is simple to use and compliant.”

The Veeva CRM Engage family of products includes Veeva CRM Engage Webinar, Veeva CRM Engage Meeting to make compliant online meetings easier and more convenient, and Veeva CRM Engage for Portals to provide HCPs with self-service online access from any device.

To learn more, register for the Veeva CRM Events Management Webinar on Thursday, 14 December at 6:00 p.m. UK time.

In other news today, Veeva announced that four of the top 20 pharmaceutical companies have adopted Veeva Align across various regions to perform fast, accurate territory alignments. Veeva also announced Veeva Vault PromoMats Brand Portal, a new digital asset management capability that makes it simple for brand managers to create portals and organize and showcase content within Veeva Vault PromoMats. Read the Veeva Align news and the Vault PromoMats Brand Portal news to learn more.

Veeva European Commercial & Medical Summit is one of the industry’s largest European events dedicated to commercial and medical solutions for life sciences. This year more than 800 life sciences professionals and industry experts will participate in the two-day conference to learn, connect, and share valuable insight on industry trends and best practices.

Additional Information

For more on Veeva CRM Engage Webinar, visit: veeva.com/eu/EngageWebinar
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 550 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s filing on Form 10-Q for the period ended 31 July, 2017. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

1 https://www.on24.com/press-releases/on24-meddata-group-study-reveals-physician-digital-behavior/

Contact information

Veeva Systems Inc.
Sue Glanville
+44 (0) 7715 817589
sue@catalystcomms.co.uk
or
Cate Bonthuys
cate@catalystcomms.co.uk
+44 (0) 7746 546773

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Philip Morris International and Dorna Switch Gears in Quest for a World without Tobacco Smoke17.11.2018 14:00Tiedote

Philip Morris International Inc. (PMI) (NYSE:PM) and Dorna Sports S.L., the commercial rights holder for the world FIM MotoGP Championships, have extended their partnership until the end of 2021. The two organizations have collaborated successfully for 26 years. As of 2019, the partnership will focus on advancing the cause of a smoke-free world. More than 1 billion people smoke today and, according to the World Health Organization, will continue to smoke in the near future. PMI has committed to transform its business and encourage all men and women who would otherwise continue smoking to replace cigarettes with better alternatives as soon as possible. With around 350 million MotoGP fans worldwide, MotoGP can play a significant role in positively impacting the lives of people who smoke and those around them. “The best choice for consumers concerned about the health risks of smoking is to quit tobacco and nicotine altogether. Today, however, technology, science and innovation provide a r

Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 21:00Tiedote

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)

Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 17:33Tiedote

Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 16:55Tiedote

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 16:15Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 15:57Tiedote

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme